{"id":9188,"date":"2020-04-23T19:02:04","date_gmt":"2020-04-23T13:32:04","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9188"},"modified":"2023-08-17T10:50:35","modified_gmt":"2023-08-17T05:20:35","slug":"recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","title":{"rendered":"AbbVie, Sofinnova back; Gilead, Kite ink; Biogen aims filing; Reversing diabetes"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a05c2d95db5f\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a05c2d95db5f\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\/#AbbVie_Sofinnova_back_USD_38_Million_for_Nitrome_Biosciences\" >AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\/#Gilead_Kite_ink_natural_killer_agreement\" >Gilead, Kite ink natural killer agreement&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\/#Biogen_targets_Quarter_3_for_aducanumab_filing\" >Biogen targets Quarter 3 for aducanumab filing<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\/#Reversing_diabetes_with_CRISPR_and_patient-derived_stem_cells\" >Reversing diabetes with CRISPR and patient-derived stem cells<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading advgb-dyn-d61257ed\"><span class=\"ez-toc-section\" id=\"AbbVie_Sofinnova_back_USD_38_Million_for_Nitrome_Biosciences\"><\/span><strong>AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Nitrome Biosciences contemplates treating <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson&#8217;s disease<\/a> and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures.<\/p>\n\n\n\n<p>The San Francisco-based biotech is focusing at a family of enzymes it discovered called nitrases. It is working on treatments that aim these enzymes to decrease or even prevent, the progression of various diseases, commencing with <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-epidemiology-forecast\">Parkinson&#8217;s<\/a>.<\/p>\n\n\n\n<p>Sofinnova and AbbVie had led the USD 38 million series A, with <a href=\"https:\/\/www.delveinsight.com\/report-store\/frontotemporal-dementia-market\">Dementia <\/a>Discovery Fund, Mission Bay Capital and Alexandria Venture Investments also pitching in. The proceeds will push Nitrome&#8217;s <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-pipeline-insight\">Parkinson&#8217;s <\/a>program toward clinical proof-of-concept studies and bolster R&amp;D efforts using Nitrome&#8217;s platform in other indications. The company is focused on other ageing-dependent diseases like other neurodegenerative disorders, heart disease and cancer, in addition to Type 2 <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-market\">diabetes<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-89f32ed8\"><span class=\"ez-toc-section\" id=\"Gilead_Kite_ink_natural_killer_agreement\"><\/span><strong>Gilead, Kite ink natural killer agreement&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Although everyone eyes Gilead Sciences&#8217; <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> hopeful remdesivir, the company is still signing deals outside of infectious disease.<\/p>\n\n\n\n<p>Through its USD 12.9 billion biotech acquire Kite Pharma, the Californian company has penned a new agreement<strong>&nbsp;<\/strong>with an almost unknown Australian biotech that is oNKo-innate.<\/p>\n\n\n\n<p>The aim of the deal is for Gilead and Kite to tap into the biotech&#8217;s natural killer (NK) work to seek out new <a href=\"https:\/\/www.delveinsight.com\/report-store\/diffuse-large-b-cell-lymphoma-pipeline-insight\">cell therapies<\/a> and build on its <a href=\"https:\/\/www.delveinsight.com\/report-store\/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market\">CAR-T <\/a>research. The deal will eye oNKo-innate use genome-wide screening techniques and its tech to quest new immune cell targets that enhance NK cell anti-tumour immunity and to create NK cell therapies.<\/p>\n\n\n\n<p>oNKo-innate will screen and seek out targets to seed its internal immuno-oncology discovery programs on the Gilead side. oNKo-innate will create and evaluate NK constructs for Kite&#8217;s development of next-generation cell therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-395178fd\"><span class=\"ez-toc-section\" id=\"Biogen_targets_Quarter_3_for_aducanumab_filing\"><\/span><strong>Biogen targets Quarter 3 for aducanumab filing<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Since when Biogen brought aducanumab, it is kept silent on its plans for the once-failed <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-market\">Alzheimer&#8217;s Disease<\/a>. Now, the company is revealing the truth. It will finish the application in the third quarter.<\/p>\n\n\n\n<p>The company has commenced submitting modules of a Biologics License Application (BLA) to the FDA and is preparing for a pre-BLA meeting with the agency scheduled for this summer. The analysts, who had previously estimated a potential 2020 approval, pushed their expectations out as far as 2022.<\/p>\n\n\n\n<p>The announcement comes a week after life sciences data firm said that the filing and review of Biogen&#8217;s recombinant human monoclonal antibody (mAb) aducanumab is likely to take more than was anticipated. In a report, it was pointed out that many trials for <a href=\"https:\/\/www.delveinsight.com\/report-store\/alzheimers-disease-ad-epidemiology-forecast\">Alzheimer&#8217;s <\/a>meds are at risk of delays because most patients required to test these drugs are being told to self-isolate during the <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19 pandemic<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading advgb-dyn-cec52500\"><span class=\"ez-toc-section\" id=\"Reversing_diabetes_with_CRISPR_and_patient-derived_stem_cells\"><\/span><strong>Reversing diabetes with CRISPR and patient-derived stem cells<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Insulin injections can keep <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-kidney-disease-dkd-market\">diabetes <\/a>under control, but patients still face severe complications like <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-kidney-disease-chronic-renal-failure-market\">kidney disease<\/a> and <a href=\"https:\/\/www.delveinsight.com\/report-store\/skin-and-skin-structure-infections-sssi-caused-by-bacteria-market\">skin infections<\/a>. Transplanting pancreatic tissues comprising functional insulin-producing beta cells is of limited use, as donors are fewer and patients must take immunosuppressant drugs after that.<\/p>\n\n\n\n<p>The scientists at Washington University in St. Louis have developed a way to make use of the gene-editing system CRISPR-Cas9 to edit a mutation in human-induced pluripotent stem cells (iPSCs) and then transform them into beta cells. The cells reversed preexisting <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-macular-edema-dme-market\">diabetes <\/a>in a lasting way when transplanted into mice as published in the journal Science Translational Medicine.<\/p>\n\n\n\n<p>While the researchers utilized the cells from patients with Wolfram syndrome, which is a rare childhood <a href=\"https:\/\/www.delveinsight.com\/report-store\/diabetic-gastroparesis-market-size\">diabetes <\/a>that is caused by mutations in the WFS1 gene, they put forward that the combination of gene therapy with stem cells could potentially treat other forms of diabetes as well.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbbVie, Sofinnova back USD 38 Million for Nitrome Biosciences Nitrome Biosciences contemplates treating Parkinson&#8217;s disease and diabetes by targeting a new class of enzymes. The pharma raised USD 38 million from the Sofinnova Partners and AbbVie Ventures. The San Francisco-based biotech is focusing at a family of enzymes it discovered called nitrases. It is working [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,830,647,812,794,18248,420,18249,16778,639,6790,18247],"industry":[17225],"therapeutic_areas":[17229,17240,17245],"class_list":["post-9188","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-biogen","tag-crispr","tag-diabetes","tag-gilead","tag-kite","tag-news","tag-nitrome-biosciences","tag-parkinsons-disease-4","tag-pharma-news","tag-recent-news","tag-sofinnova","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-endocrinology-and-metabolic-disorders","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Nitrome raises $38M; Gilead &amp; Kite&#039;s agreement; CRISPR updates;<\/title>\n<meta name=\"description\" content=\"Gilead and Kite to tap into the biotech&#039;s natural killer (NK) work to seek out new cell therapies and build on its CAR-T research. The deal will eye oNKo..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nitrome raises $38M; Gilead &amp; Kite&#039;s agreement; CRISPR updates;\" \/>\n<meta property=\"og:description\" content=\"Gilead and Kite to tap into the biotech&#039;s natural killer (NK) work to seek out new cell therapies and build on its CAR-T research. The deal will eye oNKo..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-23T13:32:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-17T05:20:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nitrome raises $38M; Gilead & Kite's agreement; CRISPR updates;","description":"Gilead and Kite to tap into the biotech's natural killer (NK) work to seek out new cell therapies and build on its CAR-T research. The deal will eye oNKo..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","og_locale":"en_US","og_type":"article","og_title":"Nitrome raises $38M; Gilead & Kite's agreement; CRISPR updates;","og_description":"Gilead and Kite to tap into the biotech's natural killer (NK) work to seek out new cell therapies and build on its CAR-T research. The deal will eye oNKo..","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-23T13:32:04+00:00","article_modified_time":"2023-08-17T05:20:35+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen","name":"Nitrome raises $38M; Gilead & Kite's agreement; CRISPR updates;","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News.jpg","datePublished":"2020-04-23T13:32:04+00:00","dateModified":"2023-08-17T05:20:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Gilead and Kite to tap into the biotech's natural killer (NK) work to seek out new cell therapies and build on its CAR-T research. The deal will eye oNKo..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-abbvie-sofinnova-gilead-kite-biogen#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News.jpg","width":772,"height":482,"caption":"recent-pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/23190113\/News-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biogen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CRISPR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Kite<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nitrome Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sofinnova<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Biogen<\/span>","<span class=\"advgb-post-tax-term\">CRISPR<\/span>","<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Kite<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Nitrome Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Parkinson&#039;s disease<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent news<\/span>","<span class=\"advgb-post-tax-term\">Sofinnova<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 23, 2020","modified":"Updated on Aug 17, 2023"},"absolute_dates_time":{"created":"Posted on Apr 23, 2020 7:02 pm","modified":"Updated on Aug 17, 2023 10:50 am"},"featured_img_caption":"recent-pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9188"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9188\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9192"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9188"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9188"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}